Clinical Trials Logo

Clinical Trial Summary

The incidence of immune thrombocytopenia increases with older age. This population is at risk for arterial thrombosis. Due to an increased turn-over of platelets, low-dose aspirin once daily may be insufficient in this population to protect against arterial thrombosis. This study is aimed at assessing the pharmacodynamics of aspirin once daily on platelet function in these patients.


Clinical Trial Description

The incidence of immune thrombocytopenia increases with older age. About 20% of patients who develop immune thrombocytopenia are exposed to low-dose aspirin for arterial thrombosis prophylaxis. Moreover, immune thrombocytopenia patients have an increased risk for developing arterial thrombosis as compared with matched controls from the general population. Because ITP patients have an increased turn-over of platelets and aspirin is an irreversible inhibitor of cyclooxygenase-1, aspirin taken once daily may be insufficient to provide stable inhibition of platelet function. This has been demonstrated in myeloproliferative neoplasms with a higher platelet turn-over as well; aspirin is given twice daily to these patients. In immune thrombocytopenia, epidemiological findings sustain this assumption because aspirin is not associated to an increased risk of bleeding. The primary aim of this study is to assess the residual platelet function after 75 mg aspirin intake (H24). Secondary objectives are to assess the kinetics of platelet function after daily 75 mg aspirin intake and the relation with arterial thrombosis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04912505
Study type Interventional
Source University Hospital, Toulouse
Contact Guillaume MOULIS, MD PhD
Phone 05 61 77 58 94
Email moulis.g@chu-toulouse.fr
Status Recruiting
Phase Phase 2
Start date January 16, 2023
Completion date September 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04003220 - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Not yet recruiting NCT03692754 - Atorvastatin in Management of Newly Diagnosed ITP Phase 2/Phase 3
Recruiting NCT05914441 - Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry
Completed NCT00010387 - Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease Phase 2
Active, not recruiting NCT00315419 - Identifying Characteristics of Bone Marrow Failure Syndromes N/A
Recruiting NCT06291415 - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) Phase 1
Completed NCT00005302 - Drug Etiology of Aplastic Anemia and Related Dyscrasias N/A